# Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

> **NCT03435952** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Malignant Neoplasm of Breast
- Malignant Neoplasms of Digestive Organs
- Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System
- Malignant Neoplasms of Female Genital Organs
- Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites
- Malignant Neoplasms of Independent (Primary) Multiple Sites
- Malignant Neoplasms of Lip Oral Cavity and Pharynx
- Malignant Neoplasms of Male Genital Organs
- Malignant Neoplasms of Mesothelial and Soft Tissue
- Malignant Neoplasms of Respiratory and Intrathoracic Organs
- Malignant Neoplasms of Thyroid and Other Endocrine Glands
- Malignant Neoplasms of Urinary Tract

## Interventions

- **DRUG:** Pembrolizumab
- **BIOLOGICAL:** Clostridium Novyi-NT
- **DRUG:** Doxycycline

## Key facts

- **NCT ID:** NCT03435952
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-07-10
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03435952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03435952, "Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03435952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*